Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

April 24, 2024

Conditions

Glioblastoma MultiformeGlioblastoma, AdultGlioma of BrainGlioblastoma Multiforme of Brain

Interventions

DRUG

IMA950/Poly-ICLC

IMA950 mixed with Poly-ICLC administered subcutaneously

DRUG

IMA950/Poly-ICLC and pembrolizumab

IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab

Trial Locations (1)

University Hospitals of Geneva, Geneva

All Listed Sponsors

lead

University Hospital, Geneva

OTHER

NCT03665545 - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma | Biotech Hunter | Biotech Hunter